Latest Candel Therapeutics News & Updates

See the latest news and media coverage for Candel. We track all announcements, press releases, and industry mentions in real time, all in one place.

Candel Therapeutics (Candel)

Clinical-stage biotech developing viral immunotherapy platforms for solid tumors

candeltx.com

Headquarters: Needham, United States
Founded year: 1999
Company type: Public company
Number of employees: 90–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Candel Therapeutics (Candel)

In short: Candel prepared for a Q4 2026 BLA submission for its lead prostate cancer therapy following positive Phase 3 results and funding deals.

Company announcements

August 20 Candel

Candel advances its prostate cancer immunotherapy development pipeline

The company reports that phase 3 trials demonstrated meaningful improvements in disease-free survival for patients receiving the viral therapy alongside radiotherapy.

August 13 Candel

Candel reports Q2 2026 financial results and corporate progress

It plans a BLA submission for aglatimagene in prostate cancer in Q4 2026, with cash runway into Q1 2028, and highlighted phase 3 data published in The Lancet Oncology.

August 3 Candel

Candel presents new prostate cancer trial data at ASTRO 2026

Chief Scientific Officer Francesca Barone MD, PhD shares findings on quantitative digital pathology and immune activation from the aglatimagene besadenovec phase 3 trial.

June 30 Candel

Candel initiates Phase 3 AURORA trial for aglatimagene in NSCLC

The global phase 3 trial will evaluate aglatimagene plus valacyclovir and pembrolizumab versus docetaxel in metastatic NSCLC patients with prior progression.

Media coverage

Today BigGo Finance

Candel CEO Paul Peter Tak: A 45-Minute Outpatient Procedure Doubled Survival in Therapy-Resistant Lung Cancer

Candel Therapeutics CEO Paul Peter Tak laid out a case for a single off-the-shelf viral immunotherapy that works across prostate, lung, and ...

September 14 Timothy Sykes

CADL Slides As Form 144 Filing Flags Insider Selling Risk

Candel Therapeutics Inc. stocks have been trading down by -8.21 percent following negative sentiment around its latest ...

August 28 Finanzen.at

Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL

(RTTNews) - The following biotech stocks reached a 52-week high on August 27, 2026, driven by key catalysts like various regulatory milestones.

August 20 Yahoo Finance

Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed?

Candel Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$38.91 million, up sharply from US$4.8 ...

Never miss news about Candel

Track Candel and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Candel competitors & trending companies

Browse news for competitors to Candel and other trending companies.